The effect of time-of-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: Evidence for dosing flexibility with a Dual Delayed Release proton pump inhibitor

Alimentary Pharmacology and Therapeutics

Volumn 31, Issue 9, 2010, Pages 1001-1011

  Lee, R D ^a   Mulford, D ^a   Wu, J ^a   Atkinson, S N ^a  

^a TAKEDA PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXLANSOPRAZOLE MR; PROTON PUMP INHIBITOR; UNCLASSIFIED DRUG; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; ANTIULCER AGENT; DELAYED RELEASE FORMULATION; LANSOPRAZOLE;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CHRONOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG EFFECT; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL PAIN; HEADACHE; HUMAN; HUMAN EXPERIMENT; LABORATORY TEST; MALE; MAXIMUM PLASMA CONCENTRATION; MEAL; NAUSEA AND VOMITING; NORMAL HUMAN; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIDE EFFECT; SPONTANEOUS ABORTION; STEADY STATE; STOMACH PH; TIME TO MAXIMUM PLASMA CONCENTRATION; VITAL SIGN; ADOLESCENT; BLOOD; DELAYED RELEASE FORMULATION; MIDDLE AGED; PHARMACOKINETICS; THERAPEUTIC USE; TIME; TREATMENT OUTCOME; YOUNG ADULT;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; ANTI-ULCER AGENTS; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DEXLANSOPRAZOLE; FEMALE; HUMANS; LANSOPRAZOLE; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77950576752     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04272.x     Document Type: Article

References (34)

1. + ATPase. Annu Rev Pharmacol Toxicol 1995 35 : 277 305.
2. Sostek MB, Chen Y, Andersson T. Effect of timing of dosing in relation to food intake on the pharmacokinetics of esomeprazole. Br J Clin Pharmacol 2007 64 : 386 390. (Pubitemid 47283859)
3. Vaz-da-Silva M, Loureiro AI, Nunes T, et al. Bioavailability and bioequivalence of two enteric-coated formulations of omeprazole in fasting and fed conditions. Clin Drug Investig 2005 25 : 391 399. (Pubitemid 41019986)
4. Bergstrand R, Grind M, Nyberg G, Olafsson B. Decreased oral bioavailability of lansoprazole in healthy volunteers when given with a standard breakfast. Clin Drug Invest 1995 9 : 67 71.
5. Delhotal-Landes B, Cournot A, Vermerie N, Dellatolas F, Benoiot M, Flouvat B. The effect of food and antacids on lansoprazole absorption and disposition. Eur J Drug Metab Pharmacokinet 1991 3 : 315 320.
6. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005 100 : 190 200. (Pubitemid 41623288)
7. Scarpignato C, Pelosini I, Di Mario F. Acid suppression therapy: where do we go from here? Dig Dis 2006 24 : 11 46. (Pubitemid 43747929)
8. Gunaratnam NT, Jessup TP, Inadomi J, Lascewski DP. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2006 23 : 1473 1477.
9. Chey WD, Inadomi JM, Booher AM, Sharma VK, Fendrick AM, Howden CW. Primary-care physicians' perceptions and practices on the management of GERD: results of a national survey. Am J Gastroenterol 2005 100 : 1237 1242.
10. Sachs G. Proton pump inhibitors and acid-related diseases. Pharmacotherapy 1997 17 : 22 37. (Pubitemid 27057116)
11. Sachs G, Shin J, Vagin O, Lambrecht N, Yakubov I, Munson K. The gastric H,K ATPase as a drug target: past, present, and future. J Clin Gastroenterol 2007 41 (Suppl. 2 S226 42. (Pubitemid 46956139)
12. Metz DC, Vakily M, Dixit T, Mulford D. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy. Aliment Pharmacol Ther 2009 29 : 928 937.
13. Vakily M, Zhang W, Wu J, Atkinson SN, Mulford D. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel dual delayed release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials. Curr Med Res Opin 2009 25 : 627 638.
14. Sharma P, Shaheen NJ, Perez MC, et al. Clinical trials: healing of erosive esophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation - results from 2 randomized controlled studies. Aliment Pharmacol Ther 2009 29 : 731 741.
15. Fass R, Chey WD, Zakko SF, et al. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2009 29 : 1261 1272.
16. Metz DC, Howden CW, Perez MC, Larsen LM, O'Neil J, Atkinson SN. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis. Aliment Pharmacol Ther 2009 29 : 742 754.
17. Peura DA, Metz DC, Dabholkar AH, Paris MM, Yu P, Atkinson SN. Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience. Aliment Pharmacol Ther 2009 30 : 1010 1021.
18. Mussig S, Witzel L, Luhmann R, Schneider A. Morning and evening administration of pantoprazole: a study to compare the effect on 24-hour intragastric pH. Eur J Gastroenterol Hepatol 1997 9 : 599 602. (Pubitemid 27267692)
19. Prichard PJ, Yeomans ND, Mihaly GW, et al. Omeprazole: a study of its inhibition of gastric pH and oral pharmacokinetics after morning or evening dosage. Gastroenterology 1985 88 : 64 9.
20. Chiverton SG, Howden CW, Burget DW, Hunt RH. Omeprazole (20 mg) daily given in the morning or evening: a comparison of effects on gastric acidity, and plasma gastrin and omeprazole concentration. Aliment Pharmacol Ther 1992 6 : 103 111.
21. +-ATPase inhibitor, on gastric pH and serum gastrin. Aliment Pharmacol Ther 1992 6 : 359 372.
22. Fraser AG, Sawyerr AM, Hudson M, Smith MS, Pounder RE. Morning versus evening dosing of lansoprazole 30 mg daily on twenty-four-hour intragastric acidity in healthy subjects. Aliment Pharmacol Ther 1996 10 : 523 527. (Pubitemid 26254795)
23. Hongo M, Ohara S, Hirasawa Y, Abe S, Asaki S, Toyota T. Effect of lansoprazole on intragastric pH. Comparison between morning and evening dosing. Dig Dis Sci 1992 37 : 882 890.
24. Thomson AB, Cohen P, Ficheux H, et al. Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: a randomized three-way crossover study. Aliment Pharmacol Ther 2006 23 : 1179 1187. (Pubitemid 43779358)
25. Baraldo M. The influence of circadian rhythms on the kinetics of drugs in humans. Expert Opin Drug Metab Toxicol 2008 4 : 175 192. (Pubitemid 351308416)
26. Lee RD, Vakily M, Mulford D, Wu J, Atkinson SN. Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor - evidence for dosing flexibility. Aliment Pharmacol Ther 2009 29 : 824 833.
27. Kapidex™ (dexlansoprazole). Full Prescribing Information.
28. ® (esomeprazole magnesium). Full Prescribing Information.
29. ® (Omeprazole). Full Prescribing Information.
30. ® (lansoprazole). Full Prescribing Information.
31. Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease - where next? Aliment Pharmacol Ther 2005 22 : 79 94. (Pubitemid 41039696)
32. Yuan Y, Thabane M, Hunt RH. Does suppression of 24-hour intragastric pH predict healing of erosive esophagitis with antisecretory treatment: a meta-analysis. Gastroenterology 2007 132 (Suppl 52 A489. Abstract.
33. Bell NJV, Burger D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992 51 : 59 67.
34. Katz PO, Ginsberg GG, Hoyle PE, Sostek MB, Monyak JT, Silberg DG. Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis. Aliment Pharmacol Ther 2007 25 : 617 628. (Pubitemid 46255854)